Strategic Acquisition Bako Diagnostics was acquired by Fulgent Genetics in December 2025, signaling potential access to larger distribution channels, capital for expansion, and enhanced diagnostic capabilities that could open co-selling opportunities and cross-promotion with Fulgent's customer base.

Podiatry Focus Specialization in podiatric pathology and lower extremity diagnostics positions Bako as a niche partner for vendors and payors serving podiatry networks, enabling targeted outreach to clinics, labs, and medical device companies focusing on foot and ankle care.

In-Network Reach With coverage spanning over 200 million lives and partnerships with major national health plans, there is a strong argument for selling expanded test menus, bundled diagnostic solutions, and value-based programs to payors seeking cost-effective, integrated podiatric testing.

Comprehensive Lab Tech Capabilities in ENFD Analysis, rapid Mass Spectrometry for culture ID, and Molecular Genetics provide multiple touchpoints for upsell of advanced diagnostics, coupled with opportunities to market streamlined workflow integrations and data sharing with EHR systems.

Growth Signals Revenue range ($50M-$100M) and a historically educational sponsorship role in the podiatric profession suggest sales opportunities around training partnerships, clinical education programs, and branded materials to drive adoption among clinicians and students.